ReviewStem cells international2021
Clinical Efficacy and Safety of Human Mesenchymal Stem Cell Therapy for Degenerative Disc Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Review in Stem cells international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Clinical efficacy and safety of somatic cell therapy for chronic low back pain: evidence from the pooled randomized controlled trials.Stem cell research & therapy · 2025Pooled it
- Mesenchymal stem cells can improve discogenic pain in patients with intervertebral disc degeneration: a systematic review and meta-analysis.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Intradiscal mesenchymal stem cell therapy for degenerative disc disease: a systematic review and meta-analysis of randomized trials.Asian spine journal · 2026Review
- From Bench to Bedside: Translational Barriers in Mesenchymal Stem Cell Therapy for Intervertebral Disc Degeneration.Bioengineering (Basel, Switzerland) · 2026Review
- Clinical application of mesenchymal stem cells in orthopaedics and traumatology in daily practice.EFORT open reviews · 2026Review
- Emerging Biologics in Lumbar Disc Degeneration: PRP, Stem Cell Therapy, and Pharmacotherapy in Mobility Restoration and Rehabilitation.Journal of spine research and surgery · 2026Article
- Comparing Regenerative Biologics and Standard Pharmacotherapy for Chronic Rotator Cuff Tendinopathy: A Study of PRP, Cell-Based, and Peptide Interventions.Journal of orthopaedics and sports medicine · 2026Article
- Intra-articular delivery of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSCs) for painful lumbar facet arthropathy: a phase I clinical trial.Stem cell research & therapy · 2025Article
- Innovative strategies in combating intervertebral disc degeneration: pathological mechanisms and biomaterial advancements.Frontiers in bioengineering and biotechnology · 2025Review
- A Proposed Diagnostic and Treatment Algorithm for the Management of Lumbar Discogenic Pain.Journal of pain research · 2025Article
- Cell-based therapy in the treatment of musculoskeletal diseases.Stem cells translational medicine · 2024Review
- Controversies regarding transplantation of mesenchymal stem cells.World journal of transplantation · 2024Review
- Review
- Stem cell therapy for degenerative disc disease: Bridging the gap between preclinical promise and clinical potential.Biomolecules & biomedicine · 2024Review
- Perspective on Intradiscal Therapies for Lumbar Discogenic Pain: State of the Science, Knowledge Gaps, and Imperatives for Clinical Adoption.Journal of pain research · 2024Article
- Research trends and hotspots of mesenchymal stromal cells in intervertebral disc degeneration: a scientometric analysis.EFORT open reviews · 2023Review
- Better isolation, proliferation and differentiation of human adipose-derived mesenchymal stem cells using human serum.European journal of translational myology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative disc disease (DDD) can cause severe low back pain, which will have a serious negative impact on the ability to perform daily tasks or activities. For the past few years, mesenchymal stem cell (MSC) transplantation has emerged as a promising strategy for the treatment of DDD. However, the clinical efficacy of MSC in the treatment of DDD still lacks clinical evidence and is controversial. We conducted a meta-analysis with randomized controlled trials (RCTs) to evaluate the clinical efficacy and safety of MSC transplantation in patients with DDD. We searched major databases using terms from the database's inception through March 2021. The Cochrane bias risk assessment tool was used to assess quality. The analysis showed that MSC therapy could decrease visual analog scale (VAS) scores (SMD = -0.50, 95%CI = -0.68 ~ -0.33,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.